Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alpha Wealth Funds - The Insiders Fund Portfolio Manager | “Insulet Corporation (NASDAQ: PODD) is a leader in medical technology, primarily known for its Omnipod Insulin Management System. Unlike traditional insulin pumps that require plastic tubing, the Omnipod is a wearable, waterproof pod that delivers insulin continuously. On May 26, 2026, Insulet had to initiate another voluntary medical device correction for specific lots of Omnipod 5, Dash, and Eros pods due to a cannula (tubing) tear that could lead to dangerous insulin under-delivery. This sent the stock price tumbling over 5% down to ~$146. On July 2, 2026, the FDA officially classified this issue as a Class I Recall, the most serious type of recall, noting it could cause serious injury or death. Despite the manufacturing overhang, the underlying business is performing exceptionally well. On May 6, 2026, Insulet reported Q1 2026 Results with massive revenue of $761.7 million (up 33.9%), easily beating estimates. Management also raised their full-year revenue guidance to 21% - 23% growth. Insulet created the category but patent protection is also expiring. They are aggressively targeting the Type 2 basal-only market, where the simplicity of a patch has much higher adoption potential. The razor-and-blade business model drives consistent recurring revenue. Insulet is not just an insulin pump company; it is a wearable drug-delivery platform. Their success with Amgen's Neulasta proves that their tubeless patch design is highly effective for oncology and could easily be adapted for other large-molecule biologics, autoimmune therapies, and targeted cancer treatments in the future.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Alpha Wealth Funds - The Insiders Fund Portfolio Manager | “Insulet created the category but patent protection is also expiring. Insulet's counter-strategy involves moving beyond Type 1 diabetes. They are aggressively targeting the Type 2 basal-only market, wh” | BULL | Q1 2026 Apr 10, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
